|
|
|
| Evaluation of the Effect of Ambroxol Hydrochloride Combined with Azithromycin in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children |
| YI Huiping, FU Feifei, LIU Yun, FU Jianping, DENG Hong, HUANG Hongmei |
| First-author's address: Xinyu Hospital of Traditional Chinese Medicine, Jiangxi Province, Xinyu 338025, China |
|
|
|
|
Abstract Objective: To explore the clinical effect of using Ambroxol Hydrochloride combined with Azithromycin in the treatment of mycoplasma pneumoniae pneumonia in children. Method: A total of 120 children with mycoplasma pneumoniae pneumonia treated in the Department of Pediatrics of Xinyu Hospital of Traditional Chinese Medicine from August 2019 to August 2022 were selected. They were equally divided into the control group (60 cases) and the observation group (60 cases) by the random number table method, Azithromycin treatment and Azithromycin combined with Ambroxol Hydrochloride treatment were administered sparately. Lung function, recovery of clinical indicators, inflammatory reaction, clinical efficacy and incidence of adverse effects were compared between the two groups. Result: Before treatment, there were no significant differences in lung function indexes between the two groups (P>0.05); after treatment, the levels of lung function indexes in the observation group were significantly higher than those in the control group, the differences were statistically significant (P<0.05). Recovery of clinical indicators of children in the observation group were significantly shorter than those in the control group (P<0.05). There were no significant differences in the levels of inflammatory factors between the two groups before treatment (P>0.05); after treatment, the levels of interleukin-6 (IL-6), C reactive protein (CRP), and serum amyloid A (SAA) in the observation group were significantly lower than those in the control group, the differences were statistically significant (P<0.05). The total clinical response rate in the observation group was significantly higher than that in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The treatment of Ambroxol Hydrochloride combined with Azithromycin in the treatment of children with mycoplasma pneumoniae pneumonia can significantly improve lung function, recovery of clinical indicators, and reduce inflammatory reactions.
|
|
Received: 11 July 2023
|
|
|
|
|
|
|
